As of June 30, 2023, cash, cash equivalents and marketable securities were $350.9 million, as compared to $220.3 million as of March 31, 2023. The company expects its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on COGT:
- Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
- Analysts Say These 2 Stocks Are Their ‘Top Picks’ for the Rest of 2023
- This Top Insider Just Scooped Up Cogent (NASDAQ:COGT) Stock Worth $9.6M
- Cogent Biosciences remains top pick into ‘derisking’ events at Piper Sandler
- Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock
Questions or Comments about the article? Write to editor@tipranks.com